Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen Extended-Release for Treatment of Spasticity in Multiple Sclerosis
2017-004100-22Phase 3Completed
- Sponsor
- Osmotica Pharmaceuticals
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Muscle spasm and multiple sclerosis (MS) comparing Arbaclofen Extended-Release with Placebo (2 arms). Started Jan 2018; status: completed.
02
Drugs
arbaclofen
03
Conditions
Muscle spasmmultiple sclerosis (MS)
Beyond the preview
Go deeper on 2017-004100-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004100-22.